Mitsubishi Tanabe to pay $1.1bn for Parkinson's drug formulator Neuroderm

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmacology, Parkinson

Mitsubishi Tanabe Pharma has agreed to pay $1.1bn (€943m) to acquire Parkinson’s disease focused formulation and drug-device developer Neuroderm Ltd.

Neuroderm’s lead product candidate – ND0612 – is a liquid formulation combining levodopa and carbidopa. The production – which is in Phase III trials in the US - is designed for continuous administration using specially developed, belt worn pump.

The Israel-based firm has a second Parkinson’s disease drug ND0701 (apomorphine) in development, as well as a transdermal CNS disease medication called ND0801 (nicotide and opipramol).

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us


View more